Skip to main content

Table 1 Demographic and clinical characteristics of the 21 patients with systemic sclerosisa

From: Systemic sclerosis sera affect fibrillin-1 deposition by dermal blood microvascular endothelial cells: therapeutic implications of cyclophosphamide

Characteristics SSc patients (N= 21)
Mean age (±SD), yr 56.5 ± 12.1
Sex, n (%)  
   Male 4 (19.1)
   Female 17 (80.9)
Disease subset, n (%)  
   lSSc 13 (61.9)
   dSSc 8 (38.1)
Mean disease duration (±SD), yrb 7.7 ± 4.1
Autoantibody positivity, n (%)  
   ANA 21 (100)
   Anti-Scl-70 7 (33.3)
   ACA 10 (47.6)
Digital ulcers, n (%) 12 (57.1)
Nailfold capillaroscopy pattern, n (%)  
   Early 4 (19.0)
   Active 8 (38.1)
   Late 9 (42.9)
Mean skin score (±SD) 10.2 ± 6.3
ILD, n (%)c 11 (52.4)
CYC treatment, n (%) 13 (61.9)d
  1. aACA, anticentromere antibodies; ANA, antinuclear antibodies; Anti-Scl-70, anti-Scl-70 antibodies; CYC, cyclophosphamide; dSSc, diffuse cutaneous systemic sclerosis; ILD, interstitial lung disease; lSSc, limited cutaneous systemic sclerosis; SSc, systemic sclerosis. Except where indicated otherwise, values are the number (%) of participants. bDisease duration was calculated from the date of the first non-Raynaud's symptom of SSc. cDetermined by high-resolution computed tomography scan. dEight patients with lSSc and five patients with dSSc.